Concepedia

Nathaniel Weygant

NW

Statistics

Publications

34

Citations

2K

H-Index

29

Active since

2011

Affiliations

University of Oklahoma Health Sciences Center(Current)

Coare Biotechnology (United States)

Oklahoma State University Oklahoma City

Fujian University of Traditional Chinese Medicine

OU Health Stephenson Cancer Center

Nathaniel Weygant is an author at University of Oklahoma Health Sciences Center specializing in medicine, oncology, and molecular oncology.

ORCID

Publications per year

2011–2022

34

Publications

34

DCLK1 Regulates Pluripotency and Angiogenic Factors via microRNA-Dependent Mechanisms in Pancreatic Cancer

Sripathi M. Sureban, Randal May, Dongfeng Qu et al. · PLoS ONE · 2013 · 148 citations · Full text

, , +17

RETRACTED ARTICLE: Dclk1, a tumor stem cell marker, regulates pro-survival signaling and self-renewal of intestinal tumor cells

Parthasarathy Chandrakesan, Jiannan Yao, Dongfeng Qu et al. · Molecular Cancer · 2017 · 122 citations · Full text

, , +17

XMD8-92 inhibits pancreatic tumor xenograft growth via a DCLK1-dependent mechanism

Sripathi M. Sureban, Randal May, Nathaniel Weygant et al. · Cancer Letters · 2014 · 118 citations

, , +8

Small molecule kinase inhibitor LRRK2-IN-1 demonstrates potent activity against colorectal and pancreatic cancer through inhibition of doublecortin-like kinase 1

Nathaniel Weygant, Dongfeng Qu, William L. Berry et al. · Molecular Cancer · 2014 · 116 citations · Full text

, , +17

DCLK1 is a broadly dysregulated target against epithelial-mesenchymal transition, focal adhesion, and stemness in clear cell renal carcinoma

Nathaniel Weygant, Dongfeng Qu, Randal May et al. · Oncotarget · 2014 · 111 citations · Full text

, , +17

1–5 of 34